Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical new chemical entities from internal discovery efforts, as well as repurposed clinical and approved drugs shown to possess novel antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.